Table 2.

Univariate Cox regression analysis of BCF in the validation cohort

Variable	HR (95% CI)	P value
32-Gene risk index	8.16 (4.07–16.37)	<0.0001
Gleason score		<0.0001
7 vs. ≤6	1.91 (1.08–3.38)	0.03
≥8 vs. ≤6	5.07 (2.76–9.31)	<0.0001
pT stage (3 vs. 2)	1.62 (0.95–2.75)	0.08
Margin (pos. vs. neg.)	2.40 (1.50–3.83)	0.0002
Log(1 + baseline PSA)	1.66 (1.23–2.24)	0.0009

The HR calculated for the 32-gene index is based on a five-unit change.